A discussion of the impact the new FDA SaMD guidance, identifying the differences between companion apps and SaMD, and what to expect from this combination in the future.
David Klein, co founder and CEO of Click Therapeutics, discusses the new FDA SaMD guidance, the clear differences between companion apps and SaMD, and gives insight into what to expect from this combination in the future.
David Benshoof Klein is a healthcare investor and entrepreneur with over 20 years of life science industry experience. Before co-founding Click Therapeutics, David was the former Managing Director at Opus Point Partners which created, financed, and operated 10+ science companies including Cougar Biotechnology (Acquired by J&J), Chelsea Therapeutics (Acquired by Lundbeck), TG Therapeutics (TGTX), Assembly Biosciences (ASMB), Tracon Pharmaceuticals (TCON), Fortress Biotech (FBIO), and Alaunos Therapeutics (TCRT).
David is also a guest faculty member at the Biotechnology Program at Columbia University, NYU Stern School of Business, and Columbia Business School.
In 2012, Mr. Klein co-founded Click Therapeutics, which develops and commercializes software as prescription medical treatments. Mr. Klein holds a bachelor’s degree from Brandeis University, and was recognized by Goldman Sachs in 2019 as one of the 100 most intriguing entrepreneurs at its annual Builders and Innovators conference. A native New Yorker, Mr. Klein is an avid art enthusiast and is co-founder of Eli Klein Gallery, America’s leading Chinese contemporary art gallery.
The editors of Pharmaceutical Executivebring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.
Listen to this podcast on SoundCloud, Spotify, Google Podcasts, or Apple Podcasts.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.